Evofem Biosciences, Inc.(EVFM US)
$0.01+0.006.90%
- Pricing and plans
Get the full experience
We save the real magic for signed-in users.
Get the full experience
We save the real magic for signed-in users.
Get the full experience
We save the real magic for signed-in users.
| Millions USD (ex. Per Share) | FY201212/31/2012 | FY201312/31/2013 | FY201412/31/2014 | FY201512/31/2015 | FY201612/31/2016 | FY201712/31/2017 | FY201812/31/2018 | FY201912/31/2019 | FY202012/31/2020 | FY202112/31/2021 | FY202212/31/2022 | FY202312/31/2023 | FY202412/31/2024 | FY202512/31/2025 | Last 12M03/31/2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.2 | 19.4 | 20.2 | 20.2 | |||||||||||||
| -Cost of Revenue | 6.5 | 3.8 | 5.1 | 5.2 | |||||||||||||
| Gross Profit | 11.7 | 15.5 | 15.1 | 15.0 | |||||||||||||
| -Operating Expenses | 29.6 | 23.2 | 13.6 | 18.5 | |||||||||||||
| +Selling, General & Admin | 26.6 | 20.7 | 17.1 | 16.6 | |||||||||||||
| +General And Administrative Expenses | 15.0 | 11.6 | 7.4 | 7.4 | |||||||||||||
| +Selling And Marketing Expenses | 11.7 | 9.2 | 9.7 | 9.2 | |||||||||||||
| +Research and Development | 2.9 | 1.8 | 3.4 | -1.1 | |||||||||||||
| +Other Operating Expenses | - | 0.6 | -6.9 | 3.0 | |||||||||||||
| Operating Income | -17.8 | -7.7 | 1.4 | -3.5 | |||||||||||||
| +Non Operating Income | 70.9 | -1.2 | -3.7 | -3.3 | |||||||||||||
| +Interest Income, Net | 0.0 | 0.0 | -2.6 | -0.7 | |||||||||||||
| +Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | |||||||||||||
| -Interest Expense | - | - | 2.6 | 0.7 | |||||||||||||
| +Other Non-Op Income | 70.8 | -1.2 | -1.0 | -2.6 | |||||||||||||
| Pretax Income | 53.0 | -8.9 | 0.4 | -6.0 | |||||||||||||
| -Income Tax Expense | 0.0 | - | 0.0 | 0.0 | |||||||||||||
| Income from Cont Ops | 53.0 | -8.9 | 0.4 | -6.1 | |||||||||||||
| -Net Extraordinary Losses | - | - | - | - | |||||||||||||
| +Discounted operations | - | - | - | - | |||||||||||||
| +XO & Accounting Changes | - | - | - | - | |||||||||||||
| Income Incl. MI | 53.0 | -8.9 | 0.4 | -6.1 | |||||||||||||
| -Minority Interests | - | - | - | - | |||||||||||||
| Net Income, GAAP | 53.0 | -8.9 | 0.4 | -6.1 | |||||||||||||
| -Prfrrd Div & Other | 3.0 | - | - | - | |||||||||||||
| Net Income Avail To Common | 50.0 | -9.0 | 0.3 | -6.2 | |||||||||||||
| Weighted Average Shs Out | 4,826,763 | 96,459,121 | 123,657,915 | 492,168,896 | |||||||||||||
| EPS | 10.4 | -0.1 | 0.0 | -0.0 | |||||||||||||
| Weighted Average Shs Out Dil | 984,038,574 | 96,459,121 | 6,421,746,555 | 6,790,257,536 | |||||||||||||
| EPS Diluted | 0.1 | -0.1 | - | -0.1 | |||||||||||||
| Millions USD (ex. Per Share) | FY201212/31/2012 | FY201312/31/2013 | FY201412/31/2014 | FY201512/31/2015 | FY201612/31/2016 | FY201712/31/2017 | FY201812/31/2018 | FY201912/31/2019 | FY202012/31/2020 | FY202112/31/2021 | FY202212/31/2022 | FY202312/31/2023 | FY202412/31/2024 | FY202512/31/2025 | Last 12M03/31/2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.2 | 19.4 | 20.2 | 20.2 | |||||||||||||
| -Cost of Revenue | 6.5 | 3.8 | 5.1 | 5.2 | |||||||||||||
| Gross Profit | 11.7 | 15.5 | 15.1 | 15.0 | |||||||||||||
| -Operating Expenses | 29.6 | 23.2 | 13.6 | 18.5 | |||||||||||||
| +Selling, General & Admin | 26.6 | 20.7 | 17.1 | 16.6 | |||||||||||||
| +General And Administrative Expenses | 15.0 | 11.6 | 7.4 | 7.4 | |||||||||||||
| +Selling And Marketing Expenses | 11.7 | 9.2 | 9.7 | 9.2 | |||||||||||||
| +Research and Development | 2.9 | 1.8 | 3.4 | -1.1 | |||||||||||||
| +Other Operating Expenses | - | 0.6 | -6.9 | 3.0 | |||||||||||||
| Operating Income | -17.8 | -7.7 | 1.4 | -3.5 | |||||||||||||
| +Non Operating Income | 70.9 | -1.2 | -3.7 | -3.3 | |||||||||||||
| +Interest Income, Net | 0.0 | 0.0 | -2.6 | -0.7 | |||||||||||||
| +Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | |||||||||||||
| -Interest Expense | - | - | 2.6 | 0.7 | |||||||||||||
| +Other Non-Op Income | 70.8 | -1.2 | -1.0 | -2.6 | |||||||||||||
| Pretax Income | 53.0 | -8.9 | 0.4 | -6.0 | |||||||||||||
| -Income Tax Expense | 0.0 | - | 0.0 | 0.0 | |||||||||||||
| Income from Cont Ops | 53.0 | -8.9 | 0.4 | -6.1 | |||||||||||||
| -Net Extraordinary Losses | - | - | - | - | |||||||||||||
| +Discounted operations | - | - | - | - | |||||||||||||
| +XO & Accounting Changes | - | - | - | - | |||||||||||||
| Income Incl. MI | 53.0 | -8.9 | 0.4 | -6.1 | |||||||||||||
| -Minority Interests | - | - | - | - | |||||||||||||
| Net Income, GAAP | 53.0 | -8.9 | 0.4 | -6.1 | |||||||||||||
| -Prfrrd Div & Other | 3.0 | - | - | - | |||||||||||||
| Net Income Avail To Common | 50.0 | -9.0 | 0.3 | -6.2 | |||||||||||||
| Weighted Average Shs Out | 4,826,763 | 96,459,121 | 123,657,915 | 492,168,896 | |||||||||||||
| EPS | 10.4 | -0.1 | 0.0 | -0.0 | |||||||||||||
| Weighted Average Shs Out Dil | 984,038,574 | 96,459,121 | 6,421,746,555 | 6,790,257,536 | |||||||||||||
| EPS Diluted | 0.1 | -0.1 | - | -0.1 | |||||||||||||